
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
APLI | Toronto | CAD | Real-time | |
APLIF | OTC Markets | USD | Delayed |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Name | Age | Since | Title |
---|---|---|---|
Lidija Marusic | - | 2019 | Board Observer |
Sridhar Narayan | - | - | Member of Scientific Advisory Board |
Brian Matthew Bloom | 48 | 2015 | Independent Director |
Donald D. Cilla | - | 2020 | CEO, President & Director |
Theresa Matkovits | 58 | 2018 | Lead Independent Director |
Juergen Froehlich | 69 | 2020 | Independent Director |
Lynn L. Silver | - | - | Member of Advisory Board |
Armand Balboni | 58 | 2019 | Chairman of the Board |
Dean L. Shinabarger | - | - | Member of Advisory Board |
Prakash Gowd | 61 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review